Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

  • Revenue in DKK (TTM)157.25bn
  • Net income in DKK50.54bn
  • Incorporated1931
  • Employees50.82k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Lonza Group AG44.69bn6.94bn317.35bn17.15k45.684.1328.877.1012.2141.8778.57134.940.3667----360,648.705.725.007.016.1438.6939.8215.5913.97--12.820.192431.4019.995.53-7.6717.4929.663.33
GSK plc288.06bn34.61bn589.64bn90.10k14.983.278.932.,201.505.806.9610.2011.6165.4068.4814.7114.681.3110.400.494194.850.0444.11-23.7336.904.50-4.36
Sanofi SA312.83bn49.34bn900.55bn95.44k18.111.6814.472.885.275.2733.5056.670.35911.385.73440,466.505.685.196.916.2369.4568.0615.8215.360.86132.430.231166.944.832.46-49.387.20-0.3872.28
Novo Nordisk A/S157.25bn50.54bn1.34tn50.82k34.7723.1223.628.4922.0422.0468.5433.150.83421.254.703,290,321.0026.8132.6551.9563.1283.9283.7932.1433.520.741219.080.254650.1810.914.7213.334.72-2.236.47
AstraZeneca plc320.92bn-9.13bn1.48tn83.10k--5.6531.714.61-0.7037-0.703723.6519.200.51742.025.77438,689.50-1.472.62-1.983.6674.8578.90-2.846.610.67375.850.451196.2640.5810.22-96.50-49.76-1.011.03
Data as of Aug 10 2022. Currency figures normalised to Novo Nordisk A/S's reporting currency: Danish Krone DKK

Institutional shareholders

14.60%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 08 Jul 202242.22m2.42%
Capital Research & Management Co. (World Investors)as of 30 Jun 202240.11m2.30%
Norges Bank Investment Managementas of 31 Dec 202139.88m2.29%
BlackRock Fund Advisorsas of 07 Jul 202227.13m1.56%
Alecta Pension Insurance Mutualas of 31 Dec 201927.09m1.55%
Fundsmith LLPas of 31 Dec 202122.81m1.31%
BlackRock Investment Management (UK) Ltd.as of 31 Jul 202221.52m1.24%
BlackRock Advisors (UK) Ltd.as of 06 Jul 202212.08m0.69%
Handelsbanken Fonder ABas of 31 Jul 202211.05m0.63%
Geode Capital Management LLCas of 04 Aug 202210.52m0.60%
More ▼
Data from 31 Dec 2021 - 30 Jun 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.